Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (21-30 of 219) with videos related to

Pageof 22
Sort By:
Journal of the American Academy of Dermatology|February 21, 2006
Long-term management of plaque psoriasis with continuous efalizumab therapyAlan Menter, Craig L Leonardi, Wolfram Sterry, et al.
Journal of Cutaneous Medicine and Surgery|October 24, 2017
Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community PracticesLuvneet Verma, Julia N Mayba, Melinda J Gooderham, et al.
Journal of Drugs in Dermatology : JDD|March 6, 2014
Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regionsAlan Menter, Kim A Papp, Huaming Tan, et al.
Journal of Drugs in Dermatology : JDD|November 9, 2012
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agentsKim A Papp, Bruce Strober, Matthias Augustin, et al.
Journal of Cutaneous Medicine and Surgery|March 22, 2007
Efalizumab for the treatment of psoriatic arthritisKim A Papp, Ivor Caro, Hoi M Leung, et al.
Drug Safety|July 19, 2008
Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trialTiffani Hamilton, Alan Menter, Ivor Caro, et al.
Journal of Drugs in Dermatology : JDD|February 18, 2004
Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasisAlan Menter, Mark Kosinski, Brian W Bresnahan, et al.
Journal of Cutaneous Medicine and Surgery|September 3, 2015
Predictors of Topical Use in Psoriasis Patients in the REFINE StudyMelinda J Gooderham, Melanie Poulin-Costello, Jennifer Shelton, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 27, 2025
Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasisKim A Papp, April W Armstrong, Tomokazu Koresawa, et al.
Current Medical Research and Opinion|June 7, 2008
Analytical approaches to reporting long-term clinical trial dataKim A Papp, Philippe Fonjallaz, Florence Casset-Semanaz, et al.
Pageof 22

Showing results (21-30 of 219) with videos related to

Sort By:
Pageof 22
Journal of the American Academy of Dermatology|February 21, 2006
Long-term management of plaque psoriasis with continuous efalizumab therapyAlan Menter, Craig L Leonardi, Wolfram Sterry, et al.
Journal of Cutaneous Medicine and Surgery|October 24, 2017
Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community PracticesLuvneet Verma, Julia N Mayba, Melinda J Gooderham, et al.
Journal of Drugs in Dermatology : JDD|March 6, 2014
Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regionsAlan Menter, Kim A Papp, Huaming Tan, et al.
Journal of Drugs in Dermatology : JDD|November 9, 2012
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agentsKim A Papp, Bruce Strober, Matthias Augustin, et al.
Journal of Cutaneous Medicine and Surgery|March 22, 2007
Efalizumab for the treatment of psoriatic arthritisKim A Papp, Ivor Caro, Hoi M Leung, et al.
Drug Safety|July 19, 2008
Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trialTiffani Hamilton, Alan Menter, Ivor Caro, et al.
Journal of Drugs in Dermatology : JDD|February 18, 2004
Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasisAlan Menter, Mark Kosinski, Brian W Bresnahan, et al.
Journal of Cutaneous Medicine and Surgery|September 3, 2015
Predictors of Topical Use in Psoriasis Patients in the REFINE StudyMelinda J Gooderham, Melanie Poulin-Costello, Jennifer Shelton, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 27, 2025
Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasisKim A Papp, April W Armstrong, Tomokazu Koresawa, et al.
Current Medical Research and Opinion|June 7, 2008
Analytical approaches to reporting long-term clinical trial dataKim A Papp, Philippe Fonjallaz, Florence Casset-Semanaz, et al.
Pageof 22